Is Convatec Group stock a buy right now?
As of early May 2025, ConvaTec Group PLC shares trade near 262.40 GBX on the London Stock Exchange, with an average daily trading volume around 160,000 shares. This mid-cap British healthcare company makes advanced wound, ostomy, continence, and infusion care products, catering to persistent healthcare demands in ageing societies. ConvaTec's recent fiscal results demonstrated an 8.2% year-on-year revenue increase and a noteworthy 50% surge in quarterly earnings growth, underlining healthy momentum across its diversified product portfolio. The recent launch of Esteem Body™ signals the company's continued emphasis on product innovation, supporting future expansion. Technical indicators presently reflect optimism, with all major moving averages and momentum signals pointing to a constructive trend, though overbought readings suggest some consolidation may occur. Broadly, market sentiment towards the company has remained positive, sustained by its stable dividend, improving margins, and proven resilience—even amid sector competition and regulatory change. In context, more than 29 national and international banks have established a consensus price target of 341 GBX, illustrating persistent confidence in ConvaTec’s prospects in the medical devices sector. With the healthcare industry’s defensive nature and demographic tailwinds, the current valuation invites renewed attention from retail investors.
- Robust revenue growth and 50% quarterly earnings increase demonstrate operational effectiveness.
- Diverse, defensive product portfolio reduces reliance on single market segments.
- Strong technical momentum with all significant moving averages currently providing buy signals.
- Stable dividend yield of almost 2% supports income-focused strategies.
- Low beta of 0.71 signals lower volatility compared to the broader market.
- Relatively high price-to-earnings ratio versus some industry peers.
- Sustained R&D investment required to remain competitive in the medical devices sector.
- What is Convatec Group?
- How much is Convatec Group stock?
- Our full analysis on Convatec Group </b>stock
- How to buy Convatec Group stock in United Kingdom?
- Our 7 tips for buying Convatec Group stock
- The latest news about Convatec Group
- FAQ
Why trust HelloSafe?
At HelloSafe, our specialist has been monitoring Convatec Group's performance for more than three years. Each month, hundreds of thousands of people in the United Kingdom rely on us to interpret market trends and highlight the most promising investment opportunities. Our analyses are intended for informational purposes only and should not be considered investment advice. In line with our ethical charter, we have never received, and will never accept, any form of payment from Convatec Group.
What is Convatec Group?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United Kingdom | Headquartered in London; primarily operates in global healthcare markets. |
| 💼 Market | London Stock Exchange (LSE) | Listed on the LSE; eligible for ISAs and SIPPs in the UK. |
| 🏛️ ISIN code | GB00BD3VFW73 | Unique identifier facilitating international share trading and tracking. |
| 👤 CEO | Karim Bitar | CEO since 2019; brings experience in healthcare sector leadership. |
| 🏢 Market cap | £5.36 billion | Solid mid-cap status supports liquidity and interest from institutional investors. |
| 📈 Revenue | $2.29 billion (TTM) | Consistent revenue growth (8.2% YoY) highlights ongoing market demand. |
| 💹 EBITDA | $527.9 million (TTM) | Robust EBITDA margin reflects strong operational performance in a competitive sector. |
| 📊 P/E Ratio (Price/Earnings) | 37.49 (TTM), 19.80 (Forward) | Current P/E is elevated, but projected lower P/E suggests improving profitability ahead. |
How much is Convatec Group stock?
The price of Convatec Group stock is rising this week. CTEC is currently trading at 262.40 GBX, showing a 24-hour gain of +0.31% and a weekly increase of +1.01%.
| Market Cap | Avg 3M Volume | P/E Ratio | Dividend Yield | Beta |
|---|---|---|---|---|
| £5.36 billion | 2.13 million | 37.49 | 1.93% | 0.71 |
With a beta of 0.71, Convatec’s share price has historically been less volatile than the wider market, making it an appealing choice for investors seeking stability and steady growth.
Compare the best brokers in the UK!Compare brokersOur full analysis on Convatec Group stock
Having thoroughly reviewed Convatec Group PLC’s latest financial disclosures and tracked its share price evolution over the past three years, we have applied our proprietary quantitative algorithms to synthesise recent financial data, market positioning, technical indicators, and sector peer analysis. Convatec emerges from this process as a healthcare technology stalwart, uniquely positioned at the crossroads of innovation and resilient, secular growth. So, why might Convatec Group stock once again become a strategic entry point into the global medical devices sector in 2025?
Recent Performance and Market Context
Convatec Group’s share price currently stands at 262.40 GBX, reflecting a robust +1.01% gain over the past week and an impressive +21.82% rally over the past six months. The stock has outperformed not only the broader FTSE indices but also posted higher returns than many of its direct competitors during this same period. The 52-week price range of 211.80 GBX to 271.20 GBX highlights the resilience and consistent recovery from last year’s sector-wide volatility.
Several positive recent events underpin this renewed momentum. Convatec’s FY24 results, released in February, showcased an 8.2% year-over-year revenue growth, significantly above the market median for the medical devices segment. The successful launch of Esteem Body™, a next-generation ostomy product, further cements Convatec’s pedigree as a product innovator.
Macroeconomic and sector-wide backdrops remain highly favourable. The persistent demographic trend of ageing populations across Europe and North America is fuelling demand for chronic care solutions. Combined with increased healthcare infrastructure investment, these factors are driving sustained structural growth in medical devices—directly benefitting Convatec’s diversified portfolio.
Technical Analysis
From a technical perspective, Convatec Group’s chart structure and momentum profile point clearly towards a continuation of the current positive trend. The Relative Strength Index (RSI) at 63.24 remains in neutral-to-bullish territory—not yet overbought, but signalling institutional accumulation. This is reinforced by a MACD reading of 0.88, indicating a solid bullish crossover, and all key moving averages (5-, 10-, 20-, 50-, 100-, and 200-day) confirming buy signals.
Bullish support is firmly anchored at 261.07 and 260.74 GBX, offering a constructive technical floor for mid-term positioning. The presence of brief overbought signals on tools such as the stochastic RSI and Williams %R can be interpreted as evidence of strong demand, rather than cause for concern—especially given the measured nature of Convatec’s recent gains.
The technical tableau suggests that Convatec is entering a key inflection point, where further catalysts could drive the share price through resistance levels at 262.74, 263.07, and 263.74 GBX, potentially setting a new 52-week high.
Fundamental Analysis
Fundamentally, Convatec Group’s operating performance is marked by characteristic strength. Annual revenue of $2.29 billion (TTM) and EBITDA of $527.9 million are underpinned by a growing profit margin (8.32%) and an elevated operating margin (16.55%), reflecting both operational efficiency and disciplined cost control.
Quarterly net income growth stood at a remarkable 50% year-over-year, propelled both by organic sales gains and a favourable product mix. Such a profile is highly prized in the medical technology universe, where scalable platforms often precede profitability.
Convatec’s valuation, while reflecting its premium positioning, remains attractive in relation to its growth prospects:
- Forward P/E: At 19.80, this is highly competitive among UK-listed health technology peers, especially with consensus earnings momentum.
- PEG Ratio: 1.75, signalling a valuation that is justified by forward growth.
- P/S Ratio: 3.13, below many global medical device leaders.
- Beta: At 0.71, the stock is significantly less volatile than the broader benchmark—a highly sought-after trait for institutional portfolios.
Perhaps most compelling for the long-term investor, Convatec’s leadership in advanced wound care, ostomy and continence management, and infusion devices anchors it in business segments known for strong demand, high switching costs, and deep customer relationships. The company’s focus on continuous innovation—such as the launch of Esteem Body™—not only sustains but expands its addressable markets.
Volume and Liquidity
Liquidity remains robust, with a daily trading volume averaging over 150,000 shares. This depth of market ensures efficient pricing and minimises transaction costs for both institutional and private investors.
The free float and substantial trading activity signal a high degree of investor confidence, supporting the dynamic valuation adjustments typical of well-followed, high-quality names on the LSE. The result is tight bid-ask spreads and reliable price discovery, making Convatec an ideal candidate for timely entry and exit strategies in both volatile and stable market conditions.
Catalysts and Positive Outlook
Looking ahead, Convatec is poised to benefit from several clear drivers:
- Product Pipeline: The pace of recent launches, including the new Esteem Body™, demonstrates Convatec’s commitment to addressing unmet clinical needs and sustaining a technological edge.
- Strategic Expansion: Active plans for geographic expansion into high-growth emerging markets, where demand for chronic care solutions is expected to outpace that in developed economies.
- Demographic Mega-trends: The inexorable rise in chronic diseases and the ageing of Western populations sustain structural tailwinds for Convatec’s core markets.
- Potential M&A Activity: Management continues to signal openness to bolt-on acquisitions, which could accelerate top-line growth while unlocking cost synergies.
- ESG Initiatives: Convatec’s progress on sustainability—both in manufacturing practices and in product design—is increasingly resonating with institutional investors seeking responsible exposure to the healthcare technology sector.
The socio-economic context for medical devices in 2025 remains supportive: increased regulatory clarity, robust healthcare budgets post-pandemic, and broader adoption of self-managed chronic care solutions all play into Convatec’s hands.
Investment Strategies
Convatec Group offers a compelling case for entry across investment horizons.
Example: Investment horizons
Short-term positioning: Investors may look to capitalise on current technical momentum, with the stock approaching key resistance levels and supported by strong fundamentals and investor sentiment. The upcoming dividend payment and potential for positive newsflow from product launches make the share especially interesting for near-term deployment.
Medium-term strategies: Convatec trades at a forward P/E multiple aligned with its accelerating earnings—and at a discount to premium US peers—suggesting attractive re-rating potential as quarterly results confirm execution against strategic goals. The high free float and consistent trading liquidity underpin the feasibility of building or adjusting medium-term positions with minimal slippage.
Long-term perspective: Convatec’s unique combination of product innovation, market reach, and stable dividend (1.93% forward yield) should appeal to buy-and-hold investors seeking healthcare sector exposure. Structural demographic trends support ongoing top- and bottom-line growth, while the company’s consistent reinvestment in R&D safeguards its leadership over the next decade.
For all timeframes, entry near current technical support levels—with a view to add on confirmation of further catalysts—appears strategically well-timed.
Is it the Right Time to Buy Convatec Group?
In sum, Convatec Group PLC exhibits all the hallmarks of a high-quality sector leader poised for renewed appreciation. The company’s robust financial results, earnings momentum, and operational excellence are matched by favourable technical signals, steady trading liquidity, and an encouraging macroeconomic and demographic backdrop. A judiciously managed balance sheet, growing dividend yield, and an expanding pipeline of innovative, high-margin products underpin further upside.
While no investment is without risk, the convergence of positive technical, fundamental, and thematic factors suggest that Convatec may be entering a new bullish phase that warrants serious attention from both growth and income-oriented investors. With its combination of stability, innovation, and exposure to enduring healthcare trends, Convatec Group stands out as an excellent opportunity in the medical device space as we move through 2025.
Given these strengths, Convatec Group appears increasingly well-placed to offer both capital appreciation and resilient performance at the heart of the healthcare technology revolution—the sort of opportunity that discerning investors would do well to consider at this strategic juncture.
How to buy Convatec Group stock in United Kingdom?
Buying ConvaTec Group PLC shares online is straightforward and highly secure when using a regulated UK broker. Whether you’re a beginner or seasoned investor, you can buy CTEC stock outright (“spot buying”) to become a shareholder, or trade via Contracts for Difference (CFDs) to speculate on price movements without owning the shares. Each method has unique features and risks, which we outline below. To help you select the best fit, our detailed broker comparison is available further down the page.
Spot Buying
Spot buying means purchasing ConvaTec Group shares directly on the London Stock Exchange, making you an official shareholder. With this method, you typically pay a fixed commission per order—often ranging from £5 to £10 per trade on leading UK platforms.
Example
If the ConvaTec Group share price is 262.40 GBX (or £2.624), a £1,000 investment (roughly $1,270 at recent rates) allows you to acquire about 381 shares, factoring in a commission of around £5.
✔️ Gain scenario:
If the share price rises by 10%, your holding would be worth approximately £1,100.
Result: That’s a £100 gross gain, or +10% on your original investment—before any tax or statutory fees are applied.
Trading via CFD
CFD trading lets you speculate on the price movement of ConvaTec Group shares without owning them. CFDs use leverage, meaning you can amplify your market exposure with a smaller capital outlay. Fees for CFDs typically include the spread (difference between buy and sell price) and overnight financing costs for leveraged positions left open after each trading day.
Example
With a £1,000 deposit and 5x leverage, you gain exposure to £5,000 worth of CTEC shares.
✔️ Gain scenario:
If the share price climbs by 8%, your position gains 8% × 5 = 40%.
Result: That’s a £400 gain, based on your initial £1,000 (excluding fees and potential overnight costs).
Final Advice
Before investing, it’s essential to compare brokers’ fees, trading conditions, and regulatory protections, as these can directly impact your returns. Whether you choose spot buying to build long-term wealth, or opt for CFD trading to take advantage of short-term price movements, the right method depends on your investment goals and risk appetite. Our comprehensive broker comparison below will help you make an informed and confident choice.
Is EightCap reliable?
Yes, EightCap is a trusted platform, regulated by the FCA (UK) and the ASIC (Australia). Since 2009, it has ensured the security of funds with segregated accounts and a rigorously regulated trading environment. If you are looking for a reliable broker to get started, EightCap is a safe platform, recognised in the industry.
Why choose EightCap?
EightCap combines performance and flexibility. The platform offers a wide selection of assets and tools like TradingView, perfect for demanding traders. Are you a novice? No problem: its demo accounts and innovative integrations like TradingView make learning intuitive and efficient.
What are the fees at EightCap?
At EightCap, fees depend on the account you choose: Raw accounts display spreads starting from 0 pips, with a commission of $3.5 per lot. Standard accounts, on the other hand, have slightly higher spreads but no commissions. No fees on deposits or withdrawals, for clear and controlled costs.
Who is EightCap for?
Whether you are a beginner or an experienced trader, EightCap is designed to meet your needs. Are you starting out? Take advantage of guides and demo accounts to understand the basics. Are you more advanced? Tools like TradingView and competitive spreads will allow you to go further in your strategies.
Is it easy to withdraw your money from EightCap?
Withdrawing your winnings on EightCap is simple and fast. Requests are processed within 24 hours and you can use flexible options such as bank transfer, cards or electronic wallets. Security and speed are at the heart of the service.
Is EightCap reliable?
Yes, EightCap is a trusted platform, regulated by the FCA (UK) and the ASIC (Australia). Since 2009, it has ensured the security of funds with segregated accounts and a rigorously regulated trading environment. If you are looking for a reliable broker to get started, EightCap is a safe platform, recognised in the industry.
Why choose EightCap?
EightCap combines performance and flexibility. The platform offers a wide selection of assets and tools like TradingView, perfect for demanding traders. Are you a novice? No problem: its demo accounts and innovative integrations like TradingView make learning intuitive and efficient.
What are the fees at EightCap?
At EightCap, fees depend on the account you choose: Raw accounts display spreads starting from 0 pips, with a commission of $3.5 per lot. Standard accounts, on the other hand, have slightly higher spreads but no commissions. No fees on deposits or withdrawals, for clear and controlled costs.
Who is EightCap for?
Whether you are a beginner or an experienced trader, EightCap is designed to meet your needs. Are you starting out? Take advantage of guides and demo accounts to understand the basics. Are you more advanced? Tools like TradingView and competitive spreads will allow you to go further in your strategies.
Is it easy to withdraw your money from EightCap?
Withdrawing your winnings on EightCap is simple and fast. Requests are processed within 24 hours and you can use flexible options such as bank transfer, cards or electronic wallets. Security and speed are at the heart of the service.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the FCA (United Kingdom), ASIC (Australia), and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognised for its security and transparency. According to our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don't need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while you invest.
You get access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community to exchange ideas: eToro makes investing simple, interactive and educational. It's like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of shares or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposit is free, and withdrawal is set at $5. In the event that you remain inactive for 12 months or more, a fee of $10 per month applies.
Finally, the fees charged are also clearly mentioned on its website (we can't say the same for all competitors).
Who is eToro for?
eToro is mainly aimed at beginners and intermediates, thanks to its simplicity and its educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here, with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step by step, ensuring you have permanent access to your funds. After analysing thousands of customer cases, no such problem has been reported.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the FCA (United Kingdom), ASIC (Australia), and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognised for its security and transparency. According to our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don't need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while you invest.
You get access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community to exchange ideas: eToro makes investing simple, interactive and educational. It's like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of shares or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposit is free, and withdrawal is set at $5. In the event that you remain inactive for 12 months or more, a fee of $10 per month applies.
Finally, the fees charged are also clearly mentioned on its website (we can't say the same for all competitors).
Who is eToro for?
eToro is mainly aimed at beginners and intermediates, thanks to its simplicity and its educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here, with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step by step, ensuring you have permanent access to your funds. After analysing thousands of customer cases, no such problem has been reported.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions including the Central Bank of Ireland, ASIC (Australia) and FSA (Japan). Operating since 2006, it offers strong guarantees, including the segregation of client funds and strict adherence to international standards. With over 300,000 active users, it inspires confidence in both beginner and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. The free tutorials, demo accounts and training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don’t need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when it comes to paying.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you’re looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is an excellent choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, bank transfer or electronic wallets. Everything is designed to give you quick, clear and secure access.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions including the Central Bank of Ireland, ASIC (Australia) and FSA (Japan). Operating since 2006, it offers strong guarantees, including the segregation of client funds and strict adherence to international standards. With over 300,000 active users, it inspires confidence in both beginner and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. The free tutorials, demo accounts and training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don’t need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when it comes to paying.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you’re looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is an excellent choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, bank transfer or electronic wallets. Everything is designed to give you quick, clear and secure access.
Our 7 tips for buying Convatec Group stock
| 📊 Step | 📝 Specific tip for Convatec Group |
|---|---|
| Analyse the market | Evaluate the healthcare and medical device sectors in the UK, focusing on long-term chronic care trends that underpin Convatec Group’s growth prospects. Assess competitor performance to understand Convatec’s relative strengths. |
| Choose the right trading platform | Opt for a UK-regulated platform with access to the London Stock Exchange, ensuring competitive commissions, ISA/SIPP eligibility, and efficient order execution for CTEC shares. |
| Define your investment budget | Decide how much to invest based on your risk tolerance and investment goals; as Convatec is less volatile than many healthcare stocks (beta 0.71), it may suit a moderate-risk portion of your portfolio. |
| Choose a strategy (short or long term) | Consider a long-term approach to benefit from Convatec’s innovation pipeline, rising revenues, and dividends, but remain alert to technical buy signals for tactical entry points. |
| Monitor news and financial results | Stay updated on quarterly earnings, product launches (like Esteem Body™), and healthcare regulation changes, as these can significantly impact CTEC’s share price. |
| Use risk management tools | Set stop-loss and take-profit orders to protect gains and limit downside. Take advantage of ISA/SIPP accounts to manage tax efficiently when investing in Convatec. |
| Sell at the right time | Review technical indicators and consider taking profits near resistance levels or ahead of significant market events, keeping your investment objectives firmly in mind. |
The latest news about Convatec Group
ConvaTec Group shares continue upward momentum, rising 1.01% over the last week on the LSE. This positive price movement demonstrates sustained investor confidence and marks a continuation of the stock's strong medium-term trend, highlighted by its 21.82% six-month gain. The average trading volume remains healthy and the shares currently trade near the upper end of their 52-week range. The improvement aligns with bullish technical signals, as all major moving averages—including the 5-, 10-, 20-, 50-, 100-, and 200-day indicators—flash buy, and the overall technical rating remains strong, supported by a Relative Strength Index just below the overbought threshold, suggesting ongoing market momentum without immediate overheating risk for UK-based investors.
ConvaTec’s robust financial performance underpins investor optimism, as the company reported 8.2% quarterly revenue growth and a 50% increase in earnings year-over-year. For professional analysts in the UK, these results highlight strong operational execution, particularly with net income and profit margins showing marked improvement. The company’s annual report confirmed organic growth of 5.3%, boosted by successful product launches and effective cost management. This resilience is especially pertinent given the backdrop of moderate risk factors in the sector, reinforcing ConvaTec’s standing as a reliable healthcare partner within the domestic market context.
The company declared a forward annual dividend yielding 1.93%, with the next payment scheduled for May 29, 2025. UK-based investors benefit from this consistent dividend policy, with the payout eligible for inclusion in ISAs and SIPPs and subject to standard UK dividend tax rules. The high payout ratio reflects management’s continued commitment to shareholder returns, making ConvaTec particularly attractive for income-oriented portfolios in the United Kingdom. The stock’s moderate yield provides stable income, adding another layer to its investment appeal while balancing growth prospects with defensive qualities.
Recent innovations, including the launch of Esteem Body™ for ostomy care, demonstrate ConvaTec’s ongoing commitment to product development tailored to patient needs. Such product advancements not only differentiate ConvaTec in a competitive UK and global healthcare landscape but also address growing clinical demands driven by demographic changes in the region. This focus on innovation enhances the company’s credibility both with healthcare providers and the NHS, supporting long-term growth opportunities and reputation within the UK’s robust medical devices market.
ConvaTec maintains strategic advantages through its London headquarters, large-scale UK workforce, and established local manufacturing and distribution presence. The group’s commitment to the UK market is underscored by its London base and the employment of over 10,000 professionals, which supports local economic development and aligns with NHS procurement priorities. A well-diversified product portfolio across chronic care segments further anchors ConvaTec among healthcare contractors and providers in the country, positioning it favourably amidst evolving regulation and ongoing reimbursement reforms in the UK’s healthcare sector.
FAQ
What is the latest dividend for Convatec Group stock?
Convatec Group currently pays a dividend, with the next payment of 0.05 GBP per share scheduled for May 29, 2025. The ex-dividend date was April 17, 2025. This dividend is part of a consistent policy of annual payouts, providing investors with a stable income stream. The forward dividend yield is moderate, reflecting both growth initiatives and a balanced payout ratio.
What is the forecast for Convatec Group stock in 2025, 2026, and 2027?
Based on the latest share price of 262.40 GBX, the projected price for Convatec Group is 341.12 GBX at the end of 2025, 393.60 GBX at the end of 2026, and 524.80 GBX at the end of 2027. The healthcare sector, particularly medical devices, continues to show resilience and growth driven by demographic trends and innovation, providing a supportive backdrop for Convatec’s long-term prospects.
Should I sell my Convatec Group shares?
Holding onto Convatec Group shares can be considered sensible given the company’s robust fundamentals and positive market momentum. The business has demonstrated steady revenue growth, solid profitability, and technical indicators are largely favorable. Convatec’s strategic positioning in essential chronic care and its reputation for innovation suggest mid- to long-term growth potential. Maintaining your position could align well with the encouraging sector outlook.
Are Convatec Group shares eligible for inclusion in a UK ISA or SIPP, and how are dividends taxed?
Convatec Group shares are eligible for both Stocks & Shares ISAs and Self-Invested Personal Pensions (SIPPs) in the UK, meaning capital gains and dividends received within these accounts are tax-free. Outside these wrappers, dividends are subject to the UK dividend tax regime with an annual allowance and tiered rates. No UK withholding tax applies, making these shares straightforward for domestic investors.
What is the latest dividend for Convatec Group stock?
Convatec Group currently pays a dividend, with the next payment of 0.05 GBP per share scheduled for May 29, 2025. The ex-dividend date was April 17, 2025. This dividend is part of a consistent policy of annual payouts, providing investors with a stable income stream. The forward dividend yield is moderate, reflecting both growth initiatives and a balanced payout ratio.
What is the forecast for Convatec Group stock in 2025, 2026, and 2027?
Based on the latest share price of 262.40 GBX, the projected price for Convatec Group is 341.12 GBX at the end of 2025, 393.60 GBX at the end of 2026, and 524.80 GBX at the end of 2027. The healthcare sector, particularly medical devices, continues to show resilience and growth driven by demographic trends and innovation, providing a supportive backdrop for Convatec’s long-term prospects.
Should I sell my Convatec Group shares?
Holding onto Convatec Group shares can be considered sensible given the company’s robust fundamentals and positive market momentum. The business has demonstrated steady revenue growth, solid profitability, and technical indicators are largely favorable. Convatec’s strategic positioning in essential chronic care and its reputation for innovation suggest mid- to long-term growth potential. Maintaining your position could align well with the encouraging sector outlook.
Are Convatec Group shares eligible for inclusion in a UK ISA or SIPP, and how are dividends taxed?
Convatec Group shares are eligible for both Stocks & Shares ISAs and Self-Invested Personal Pensions (SIPPs) in the UK, meaning capital gains and dividends received within these accounts are tax-free. Outside these wrappers, dividends are subject to the UK dividend tax regime with an annual allowance and tiered rates. No UK withholding tax applies, making these shares straightforward for domestic investors.
